Structural models of human apolipoprotein A-I: a critical analysis and review

被引:216
作者
Brouillette, CG
Anantharamaiah, GM
Engler, JA
Borhani, DW
机构
[1] Univ Alabama Birmingham, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Atherosclerosis Res Unit, Birmingham, AL 35294 USA
[3] Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA
[4] BASF Biores Corp, Worcester, MA 01605 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS | 2001年 / 1531卷 / 1-2期
基金
美国国家卫生研究院;
关键词
apolipoprotein A-I mutant; high density lipoprotein; exchangeable apolipoprotein; apolipoprotein E; apolipophorin III; molten globule; HDL model; lipid binding; protein folding;
D O I
10.1016/S1388-1981(01)00081-6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human apolipoprotein (apo) A-I has been the subject of intense investigation because of its well-documented antiatherogenic properties. About 70% of the protein found in high density lipoprotein complexes is apo A-I, a molecule that contains a series of highly homologous amphiphatic alpha -helices. A number of significant experimental observations have allowed increasing sophisticated structural models for both the lipid-bound and the lipid-free forms of the apo A-I molecule to be tested critically. It seems clear, for example, that interactions between amphipathic domains in apo A-I may be crucial to understanding the dynamic nature of the molecule and the pathways by which the lipid-free molecule binds to lipid, both in a discoidal and a spherical particle. The state of the art of these structural studies is discussed and placed in context with current models and concepts of the physiological role of apo A-I and high-density lipoprotein in atherosclerosis and lipid metabolism. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:4 / 46
页数:43
相关论文
共 262 条
  • [1] Identification of scavenger receptor SR-BI as a high density lipoprotein receptor
    Acton, S
    Rigotti, A
    Landschulz, KT
    Xu, SZ
    Hobbs, HH
    Krieger, M
    [J]. SCIENCE, 1996, 271 (5248) : 518 - 520
  • [2] ANANTHARAMAIAH GM, 1986, METHOD ENZYMOL, V128, P627
  • [3] USE OF SYNTHETIC PEPTIDE ANALOGS TO LOCALIZE LECITHIN-CHOLESTEROL ACYLTRANSFERASE ACTIVATING DOMAIN IN APOLIPOPROTEIN-A-I
    ANANTHARAMAIAH, GM
    VENKATACHALAPATHI, YV
    BROUILLETTE, CG
    SEGREST, JP
    [J]. ARTERIOSCLEROSIS, 1990, 10 (01): : 95 - 105
  • [4] ANANTHARAMAIAH GM, 1991, ADV EXP MED BIOL, V285, P131
  • [5] ANANTHARAMAIAH GM, 1985, J BIOL CHEM, V260, P248
  • [6] Anantharamaiah GM, 1993, AMPHIPATHIC HELIX
  • [7] The structural basis of lipid interactions in lipovitellin, a soluble lipoprotein
    Anderson, TA
    Levitt, DG
    Banaszak, LJ
    [J]. STRUCTURE WITH FOLDING & DESIGN, 1998, 6 (07): : 895 - 909
  • [8] Pharmacology of apolipoprotein A-I
    Andersson, LO
    [J]. CURRENT OPINION IN LIPIDOLOGY, 1997, 8 (04) : 225 - 228
  • [9] A novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis
    Asl, KH
    Liepnieks, JJ
    Nakamura, M
    Parker, F
    Benson, MD
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 257 (02) : 584 - 588
  • [10] Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein A1
    Asl, LH
    Liepnieks, JJ
    Asl, KH
    Uemichi, T
    Moulin, G
    Desjoyaux, E
    Loire, R
    Delpech, M
    Grateau, G
    Benson, MD
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (01) : 221 - 227